Objective: This study aims to observe the clinical efficacy of low-dose rituximab patients with cryoglobulinaemia secondary to connective tissue diseases.
Methods: Rituximab (100 mg) was infused in patients once a week for four weeks, combined with prednisone (20 mg) once a day and reduced regularly. The treatment effect was observed regularly.
Results: Joint pain, fever, rash and fatigue symptoms in patients eased. The serology (globulin, erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase and others) parameters returned to normal.
Conclusion: Low-dose rituximab therapy for cryoglobulinaemia secondary to connective tissue diseases was safe and effective and can be used as a treatment option in this condition.